earticle

영어

The global pharma market size is estimated to be upwards of US$ 770 Billion as of 2008 and new pharmaceuticals makes a great influence on a pharmaceutical company itself and the whole country. However, considering the R&D cost and time for a new drug into the market, developing a new drug is not an easy decision even to a big pharmaceutical company. In addition, despite all the R&D cost and time, a new drug has a strong possibility of failing in the market and approval process. Therefore, pharmaceutical companies have tried a technology licensing,
which would be one of major sources to find a lead compound for a new drug. Since the technology transfer act was enacted in 2000 in Korea, there have been so many cases of licensing between a company and public R&D organization including a University. Nevertheless the R&D investment of government and the amount of patent is increasing, total amount of licensing cases and fees never match up to our expectation. There could be several reasons, however the difference in understanding of drug development process between company and R&D organization would be a major reason. A successful licensing in a bio and pharmaceutical
field depends on how well a company expresses its unmet needs and people in R&D understand the company's drug development process and prepare to meet that needs.